Sino Biopharmaceutical Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sino Biopharmaceutical Limited
Upcoming user fee goal dates include AstraZeneca’s tremelimumab, Amicus’ AT-GAA, and drug delivery technology-driven NDAs from Supernus/US Worldmeds and scPharmaceuticals
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.
A number of major Chinese pharma firms, including Simcere and Hansoh, brought in more revenues from innovative drugs than generics in the first half, a major stand-out from their domestic peers.
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
- Drug Delivery
- Generic Drugs
Drug Discovery Technologies
- Natural Products
- Molecular Diversity
- Drug Discovery Technologies
- Other Names / Subsidiaries
- Beijing Tide Pharmaceutical Co Ltd, invoX Pharma
- Jiangsu Chia Tai Tianqing Pharmaceutical Co Ltd, Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd, Qingdao Chia Tai Haier Pharmaceutical Co Ltd, Jiangsu Chia Tai Qing Jiang Pharmaceutical Co Ltd, etc. Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd